GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of cardiovascular disease.

SGLT2 inhibitors confer greater risk reductions for major adverse cardiovascular events in older adults with type 2 diabetes ...

Use of a sodium-glucose cotransporter 2, or SGLT2, inhibitor combined with calorie restriction resulted in greater rates of type 2 diabetes remission compared with calorie restriction alone, according ...

Researchers analyzed concentrations of microplastics in 91 brain tissue samples collected during autopsies in 2016 and 2024. The samples were from the frontal cortex, the brain region above and behind ...

Motilal Oswal recommended Neutral rating on Eris Lifesciences with a target price of Rs 1270 in its research report dated ...

“Our data suggest SGLT2 inhibition as a safe strategy to prevent kidney stone recurrence in patients with kidney stones ,” Dr Fuster’s team concluded. Other study findings indicate the empagliflozin ...

CardioOncology, shows that administration of the SGLT2 inhibitor empagliflozin to pigs receiving anthracyclines preserves ...

The use of SGLT2 vs DPP4 inhibitors was linked to reduced cardiovascular and renal risks among patients with comorbid SLE and T2D.

Combined strategy is effective but questions remain The view that the hyperglycaemia associated with type 2 diabetes is ...

They added that “it seems very likely that SGLT2 inhibitors will also result in a substantial reduction in recurrent stone events in patients with pure [calcium oxalate] stones.” Despite the ...